Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | Tongfei Wu, Hillary Millar, Dana Gaffney, Lijs Beke, Geert Mannens, Petra Vinken, Ivan Sommers et al. | ||||||||||||
Title | JNJ-64619178, a selective and pseudo-irreversible PRMT5 inhibitor with potent in vitro and in vivo activity, demonstrated in several lung cancer models | ||||||||||||
|
|||||||||||||
URL | https://cancerres.aacrjournals.org/content/78/13_Supplement/4859 | ||||||||||||
Abstract Text | Cancer Res 2018;78(13 Suppl):Abstract nr 4859 |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
JNJ-64619178 | JNJ-64619178 | 0 | 1 |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
JNJ-64619178 | JNJ64619178|JNJ 64619178 | PRMT5 Inhibitor 16 | JNJ-64619178 is a PRMT5 inhibitor that binds to and inhibits the S-adenosylmethionine (SAM) and substrate-binding regions of the PRMT5/MEP50 complex, potentially reducing dimethylation of target proteins such as SMD1/3 and resulting in tumor growth inhibition (Cancer Res 2018;78(13 Suppl):Abstract nr 4859, PMID: 31312965). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|